SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: July 13, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                   Delaware                           52-1555759
          (State of Incorporation)                (I.R.S. Employer
                                                  Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


        Registrant's telephone number, including area code (301) 417-0770


                  No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.



<PAGE>


MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated July 12, 1999:


FOR IMMEDIATE RELEASE
Contacts:                                Elliot Lebowitz, Ph.D.
William C. Roberts                       President and Chief Executive Officer
Investor and Media Relations             BioTransplant Incorporated
MedImmune, Inc.                          617-241-5200
301-417-0770 x358
                                         Fran DeVellis or
                                         Bruce Schiamberg
                                         Feinstein Kean Partners
                                         617-577-8110

http://www.medimune.com
http://www.biotransplant.com


MEDIMMUNE  AND  BIOTRANSPLANT  ANNOUNCE  RESULTS  OF  MEDI-507  TRIAL IN  SEVERE
STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE PATIENTS

Gaithersburg, MD, and Charlestown, MA, July 12, 1999 -- MedImmune, Inc. (Nasdaq:
MEDI)  and  BioTransplant   Incorporated  (Nasdaq:  BTRN)  today  announced  the
presentation  of data from a Phase 1/2 trial  with  MEDI-507  in  patients  with
steroid-resistant,  severe graft-versus-host disease (GvHD). In the trial, 12 of
17 participants  had improvement in their GvHD grade during the follow-up period
after treatment with MEDI-507;  10 patients  achieved a complete response (grade
0) at some point during the study. These results were presented this week at the
28th Annual Meeting of the  International  Society for Experimental  Hematology.
GvHD is a frequent and often fatal outcome of bone marrow transplantation and is
currently  treated  with   corticosteroids.   The  mortality  rate  for  serious
steroid-resistant GvHD cases is estimated to be over 70 percent.

"We are  encouraged by the responses seen in these severe GvHD patients who were
all unresponsive to standard steroid  therapy,"  commented Edward Connor,  M.D.,
Vice President of Clinical  Development at MedImmune.  "GvHD is a very difficult
disease to treat; the data from this initial trial suggest  biological  activity
for MEDI-507 in GvHD."

Using the consensus  classification based on biopsies,  seven patients with GvHD
grade II and 10 patients with GvHD grade III-IV were enrolled in this study. All
but four of the patients had gut and/or liver  involvement.  Patients received a
short regimen of four doses of 0.12 mg/kg intravenous MEDI-507 given every third
day and then  either  placebo  or  additional  doses of 0.12  mg/kg  intravenous
MEDI-507  weekly for four weeks.  Patients were followed for 100 days. Of the 17
patients in the trial,  12 improved  their grade of GvHD and 10 achieved grade 0
at some point during  follow-up.  Treatment  with  MEDI-507 was  generally  well
tolerated,  and  no  antibodies  to  MEDI-507  were  detected.  Eleven  patients
experienced  acute adverse events  associated with MEDI-507,  including  chills,
fever  and  nausea.  These  events  were  generally  mild and did not  interrupt
therapy.  Notwithstanding improvements in GvHD in certain patients, 12 of the 17
patients  ultimately  died during the 100 day period,  typically  as a result of
progression of their GvHD or complications  such as infections.  These data were
presented by the lead investigator of the study, Voravit Ratanatharathorn, M.D.,
of the University of Michigan Hospital.

Dr. Connor added,  "We have now gone on to begin a randomized,  controlled  dose
ranging  study in steroid  naive GvHD  patients.  We hope to  optimize  the dose
regimen to further improve and extend the clinical  benefit.  In addition to the
work we are doing in GvHD, we are also evaluating MEDI-507 in a Phase 1 trial in
psoriasis patients."

"MEDI-507's  ability to  selectively  block immune  responses and to prevent the
rejection  of  transplanted  cells  or  tissue  is  also  an  important  part of
BioTransplant's   ImmunoCognance(trademark)  approach,"  said  Elliot  Lebowitz,
Ph.D., President and CEO of BioTransplant.

GvHD is a clinical syndrome caused when certain white blood cells from the donor
bone marrow attack the tissue of the recipient.  Clinical manifestations include
skin   rash,   severe   diarrhea,   and  liver   abnormalities   and   jaundice.
Steroid-refractory  GvHD  occurs  when the  attacking  white  blood cells of the
foreign graft fail to respond to steroid therapy.

MEDI-507 is the humanized form of the murine monoclonal  antibody,  BTI-322.  In
pilot  clinical  trials in over 100  patients  in the United  States and Europe,
BTI-322 has suggested  potential clinical benefit in the studied populations and
has been generally  well  tolerated.  In a Phase 1/2 clinical  trial  evaluating
BTI-322 for treatment of acute  graft-versus-host  disease (GvHD) in bone marrow
transplant (BMT) patients unresponsive to steroid therapy, the compound was well
tolerated and 55 percent of the patients responded positively to treatment, with
either a complete  response or a reduction  in grade of GvHD.  A Phase 1/2 trial
has been  completed for the  prevention of acute renal  transplant  rejection in
which  BTI-322  was given at the time of organ  transplantation.  Results of the
trial  suggested  a 58 percent  reduction  at two years  post-transplant  in the
incidence of kidney graft rejection  episodes  compared to  conventional  triple
drug therapy alone. Two additional Phase 1/2 clinical trials have been developed
to evaluate MEDI-507 as treatment for acute GvHD in steroid-naive  adults and in
pediatric  patients.  MedImmune has also initiated Phase 1 studies in psoriasis,
an autoimmune disease.

Both MEDI-507 and BTI-322 bind specifically to the CD2 receptor found on T cells
and natural  killer (NK) cells.  Previous in vitro studies have  suggested  that
MEDI-507 has the ability to inhibit selectively the response of T cells directed
at transplant  antigens,  while  subsequently  allowing  immune cells to respond
normally to other antigens. BTI-322 was initially discovered by Drs. Herve Bazin
and  Dominique  Latinne  at the  Experimental  Immunology  Unit of the  Catholic
University of Louvain in Belgium.

BioTransplant Incorporated utilizes its proprietary technologies in re-educating
the body's immune  responses to allow  tolerance of foreign  cells,  tissues and
organs.  Based on this  technology,  the Company is  developing  a portfolio  of
products  designed to treat a range of medical  conditions,  including organ and
tissue  transplantation,  cancer  and  autoimmune  disease,  for  which  current
therapies  are  inadequate.  BioTransplant's  products  are  intended  to induce
long-term  functional   transplantation   tolerance  in  humans,   increase  the
therapeutic benefit of bone marrow transplants, and reduce or eliminate the need
for lifelong  immunosuppressive  therapy. MedImmune is developing MEDI-507 under
license  from  BioTransplant,  and  BioTransplant  has retained the right to use
BTI-322 and/or  MEDI-507 in its proprietary  ImmunoCognance(trademark)  systems,
which are designed to re-educate the immune system to accept foreign tissue: the
AlloMune(trademark)   System  for   human-to-human   transplantation,   and  the
XenoMune(trademark) System for porcine-to-human transplantation.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product  candidates in clinical trials.  In October
1995,   MedImmune  and  BioTransplant   established  a  strategic  alliance  for
development of BTI-322 and any future generation products, such as MEDI-507, for
use in organ transplantation and other indications.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.


                                      ####




(REGISTRANT)      MEDIMMUNE, INC.





BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            July 13, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE AND BIOTRANSPLAN ANNOUNCE RESULTS", "secsgml_size_bytes": 9890}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99663261"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: July 13, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                   Delaware                           52-1555759
          (State of Incorporation)                (I.R.S. Employer
                                                  Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

        Registrant's telephone number, including area code (301) 417-0770

                  No Exhibits are being filed with this report

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated July 12, 1999:

FOR IMMEDIATE RELEASE
Contacts:                                Elliot Lebowitz, Ph.D.
William C. Roberts                       President and Chief Executive Officer
Investor and Media Relations             BioTransplant Incorporated
MedImmune, Inc.                          617-241-5200
301-417-0770 x358
                                         Fran DeVellis or
                                         Bruce Schiamberg
                                         Feinstein Kean Partners
                                         617-577-8110

http://www.medimune.com
http://www.biotransplant.com

MEDIMMUNE  AND  BIOTRANSPLANT  ANNOUNCE  RESULTS  OF  MEDI-507  TRIAL IN  SEVERE
STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE PATIENTS

Gaithersburg, MD, and Charlestown, MA, July 12, 1999 -- MedImmune, Inc. (Nasdaq:
MEDI)  and  BioTransplant   Incorporated  (Nasdaq:  BTRN)  today  announced  the
presentation  of data from a Phase 1/2 trial  with  MEDI-507  in  patients  with
steroid-resistant,  severe graft-versus-host disease (GvHD). In the trial, 12 of
17 participants  had improvement in their GvHD grade during the follow-up period
after treatment with MEDI-507;  10 patients  achieved a complete response (grade
0) at some point during the study. These results were presented this week at the
28th Annual Meeting of the  International  Society for Experimental  Hematology.
GvHD is a frequent and often fatal outcome of bone marrow transplantation and is
currently  treated  with   corticosteroids.   The  mortality  rate  for  serious
steroid-resistant GvHD cases is estimated to be over 70 percent.

"We are  encouraged by the responses seen in these severe GvHD patients who were
all unresponsive to standard steroid  therapy,"  commented Edward Connor,  M.D.,
Vice President of Clinical  Development at MedImmune.  "GvHD is a very difficult
disease to treat; the data from this initial trial suggest  biological  activity
for MEDI-507 in GvHD."

Using the consensus  classification based on biopsies,  seven patients with GvHD
grade II and 10 patients with GvHD grade III-IV were enrolled in this study. All
but four of the patients had gut and/or liver  involvement.  Patients received a
short regimen of four doses of 0.12 mg/kg intravenous MEDI-507 given every third
day and then  either  placebo  or  additional  doses of 0.12  mg/kg  intravenous
MEDI-507  weekly for four weeks.  Patients were followed for 100 days. Of the 17
patients in the trial,  12 improved  their grade of GvHD and 10 achieved grade 0
at some point during  follow-up.  Treatment  with  MEDI-507 was  generally  well
tolerated,  and  no  antibodies  to  MEDI-507  were  detected.  Eleven  patients
experienced  acute adverse events  associated with MEDI-507,  including  chills,
fever  and  nausea.  These  events  were  generally  mild and did not  interrupt
therapy.  Notwithstanding improvements in GvHD in certain patients, 12 of the 17
patients  ultimately  died during the 100 day period,  typically  as a result of
progression of their GvHD or complications  such as infections.  These data were
presented by the lead investigator of the study, Voravit Ratanatharathorn, M.D.,
of the University of Michigan Hospital.

Dr. Connor added,  "We have now gone on to begin a randomized,  controlled  dose
ranging  study in steroid  naive GvHD  patients.  We hope to  optimize  the dose
regimen to further improve and extend the clinical  benefit.  In addition to the
work we are doing in GvHD, we are also evaluating MEDI-507 in a Phase 1 trial in
psoriasis patients."

"MEDI-507's  ability to  selectively  block immune  responses and to prevent the
rejection  of  transplanted  cells  or  tissue  is  also  an  important  part of
BioTransplant's   ImmunoCognance(trademark)  approach,"  said  Elliot  Lebowitz,
Ph.D., President and CEO of BioTransplant.

GvHD is a clinical syndrome caused when certain white blood cells from the donor
bone marrow attack the tissue of the recipient.  Clinical manifestations include
skin   rash,   severe   diarrhea,   and  liver   abnormalities   and   jaundice.
Steroid-refractory  GvHD  occurs  when the  attacking  white  blood cells of the
foreign graft fail to respond to steroid therapy.

MEDI-507 is the humanized form of the murine monoclonal  antibody,  BTI-322.  In
pilot  clinical  trials in over 100  patients  in the United  States and Europe,
BTI-322 has suggested  potential clinical benefit in the studied populations and
has been generally  well  tolerated.  In a Phase 1/2 clinical  trial  evaluating
BTI-322 for treatment of acute  graft-versus-host  disease (GvHD) in bone marrow
transplant (BMT) patients unresponsive to steroid therapy, the compound was well
tolerated and 55 percent of the patients responded positively to treatment, with
either a complete  response or a reduction  in grade of GvHD.  A Phase 1/2 trial
has been  completed for the  prevention of acute renal  transplant  rejection in
which  BTI-322  was given at the time of organ  transplantation.  Results of the
trial  suggested  a 58 percent  reduction  at two years  post-transplant  in the
incidence of kidney graft rejection  episodes  compared to  conventional  triple
drug therapy alone. Two additional Phase 1/2 clinical trials have been developed
to evaluate MEDI-507 as treatment for acute GvHD in steroid-naive  adults and in
pediatric  patients.  MedImmune has also initiated Phase 1 studies in psoriasis,
an autoimmune disease.

Both MEDI-507 and BTI-322 bind specifically to the CD2 receptor found on T cells
and natural  killer (NK) cells.  Previous in vitro studies have  suggested  that
MEDI-507 has the ability to inhibit selectively the response of T cells directed
at transplant  antigens,  while  subsequently  allowing  immune cells to respond
normally to other antigens. BTI-322 was initially discovered by Drs. Herve Bazin
and  Dominique  Latinne  at the  Experimental  Immunology  Unit of the  Catholic
University of Louvain in Belgium.

BioTransplant Incorporated utilizes its proprietary technologies in re-educating
the body's immune  responses to allow  tolerance of foreign  cells,  tissues and
organs.  Based on this  technology,  the Company is  developing  a portfolio  of
products  designed to treat a range of medical  conditions,  including organ and
tissue  transplantation,  cancer  and  autoimmune  disease,  for  which  current
therapies  are  inadequate.  BioTransplant's  products  are  intended  to induce
long-term  functional   transplantation   tolerance  in  humans,   increase  the
therapeutic benefit of bone marrow transplants, and reduce or eliminate the need
for lifelong  immunosuppressive  therapy. MedImmune is developing MEDI-507 under
license  from  BioTransplant,  and  BioTransplant  has retained the right to use
BTI-322 and/or  MEDI-507 in its proprietary  ImmunoCognance(trademark)  systems,
which are designed to re-educate the immune system to accept foreign tissue: the
AlloMune(trademark)   System  for   human-to-human   transplantation,   and  the
XenoMune(trademark) System for porcine-to-human transplantation.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product  candidates in clinical trials.  In October
1995,   MedImmune  and  BioTransplant   established  a  strategic  alliance  for
development of BTI-322 and any future generation products, such as MEDI-507, for
use in organ transplantation and other indications.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                      ####

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            July 13, 1999